10 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital
In this article, we will take a look at the 10 stocks to buy according to Neil Shahrestani's Ikarian Capital.
Relmada Therapeutics Inc. (RLMD)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 2,000,000 | $53,980 | 1.17% | |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,647,400 | $44,463 | 1.77% | |
| 3. | Point72 Asset Management Steve Cohen | 1,312,400 | $35,422 | +39% | 0.14% |
| 4. | Citadel Investment Group Ken Griffin | 939,472 | $25,356 | +220% | 0% |
| 5. | Great Point Partners Jeffrey Jay And David Kroin | 790,000 | $21,322 | +11% | 5.15% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.00 | 978 | Director | 2,228 | 2019-10-21 | Filing | |
| $19.20 | 3,100 | Director | 127,121 | 2019-10-18 | Filing | |
| $19.15 | 100 | Director | 124,021 | 2019-10-18 | Filing | |
| $19.10 | 200 | Director | 123,921 | 2019-10-18 | Filing | |
| $19.08 | 100 | Director | 123,721 | 2019-10-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.04 | 10,000 | Director | 187,295 | 2022-04-04 | Filing | |
| $29.00 | 3,300 | Director | 0 | 2022-04-01 | Filing | |
| $29.00 | 3,300 | Director | 3,300 | 2022-04-01 | Filing | |
| $29.00 | 3,300 | Director | 6,600 | 2022-04-01 | Filing | |
| $29.00 | 3,300 | Director | 9,900 | 2022-04-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 24,120 | $650,999 | 0% | |
| 2. | 2,540,074 | $68,557 | 1.41% | |
| 3. | 2,270,072 | $61,269 | 9.92% | |
| 4. | 1,952,808 | $52,707 | 0% | |
| 5. | 1,324,014 | $35,736 | 0% |
News See All
Is RLMD A Good Stock To Buy Now?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
Hedge Funds Are Nibbling On Relmada Therapeutics, Inc. (RLMD)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
